Trials / Completed
CompletedNCT06063889
Maximal Rate of Force Development of Ankle Muscles and Functional Ability in Patients With Knee Osteoarthritis
Assessment of Maximal Rate of Force Development of Ankle Muscles and Its Association Functional Ability in Patients With Knee Osteoarthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 126 (actual)
- Sponsor
- Ahram Canadian University · Academic / Other
- Sex
- All
- Age
- 30 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a detailed assessment of the maximal rate of force development of ankle muscles and its association with functional ability in patients with knee osteoarthritis (OA).
Detailed description
This research is designed to study the link between force development in ankle muscles and functional abilities in knee OA patients. It aims to understand the influence of ankle muscle strength, specifically plantar flexors, on the stability, pain, and functionality of patients with knee OA. The study will analyze the rate of force development, its importance in explosive strength improvement, and impact on preventing knee injuries. Furthermore, it will investigate the compensatory mechanism of the plantar flexors developed by patients in advanced stages to balance other muscle failures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Maximal Rate of Force Development Test for Ankle Muscles | This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis. |
Timeline
- Start date
- 2023-07-20
- Primary completion
- 2024-02-02
- Completion
- 2024-02-02
- First posted
- 2023-10-03
- Last updated
- 2024-08-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06063889. Inclusion in this directory is not an endorsement.